Get 10% discount on your first purchase with code

Welcome10
Cart
Sale!
Semaglutide
Semaglutide - Image 2

Semaglutide

⭐ See Our ReviewsPilot Profile

Semaglutide is a GLP-1 receptor agonist. It is a peptide similar to the hormone GLP-1 and is used extensively in metabolic research for its potential effects on glucose metabolism.

You'll also need Bacteriostatic Water

Required to reconstitute lyophilized peptides before use in research.

You may also like…

Delivery in 1-3 days
Free shipment protection
Overnight shipping available

Free shipping

on orders over £100

60-day money-back

guarantee

Secure checkout

256-bit SSL

4,114

MOLECULAR WEIGHT

Daltons

31

AMINO ACIDS

Peptide sequence

2,500+

STUDIES

Published research

99%+

PURITY

HPLC verified

Product Details

  • Molecular Formula: C187H291N45O59
  • Molecular Weight: 4113.58 g/mol
  • Appearance: White lyophilized powder
  • Storage: Store at -20°C
  • Purity: ≥99% (HPLC)
  • Research Use Only
  • Clinical Research Results

Key findings from published peer-reviewed research studies.

14.9%

Avg Weight Loss

20%

CV Event Reduction

2,500+

Published Studies

~7d

Half-Life

Weight Management (STEP Trials)

Average body weight reduction of 14.9% over 68 weeks

The STEP 1 trial demonstrated that weekly semaglutide 2.4mg produced a mean weight loss of 14.9% compared to 2.4% with placebo, establishing a new benchmark in obesity research.

Cardiovascular Outcomes

20% reduction in major adverse cardiovascular events (SELECT trial)

The SELECT cardiovascular outcomes trial showed a significant reduction in the composite endpoint of cardiovascular death, non-fatal MI, and non-fatal stroke.

Glycemic Efficacy (SUSTAIN Program)

HbA1c reductions of up to 1.8% from baseline

Across the SUSTAIN trial series, semaglutide demonstrated superior glycemic control versus multiple active comparators, with durable effects over 2+ years.

Hepatic Benefits

Improvements in non-alcoholic steatohepatitis (NASH) markers

Research has shown reductions in liver fat content, liver enzyme levels, and histological improvements in NASH, supporting potential hepatoprotective properties.

  • Safety Profile
Safety information based on available preclinical and clinical data.

Low

Hypoglycemia Risk

15-20%

Nausea Incidence

Safe

CV Profile

Gastrointestinal Effects

Nausea (15-20%), diarrhea, vomiting, and constipation are the most common. Dose titration protocols help mitigate these effects.

Pancreatic Safety

No significant increase in acute pancreatitis risk observed in large-scale trials. Regular monitoring of pancreatic enzymes is recommended in research protocols.

Gallbladder Events

Slightly increased incidence of cholelithiasis and cholecystitis observed, potentially related to rapid weight loss rather than direct drug effect.

Retinopathy Monitoring

In diabetic subjects, early worsening of retinopathy has been reported with rapid glycemic improvement. Gradual dose escalation is recommended.

Contraindications

Research use only. Not for subjects with personal/family history of medullary thyroid carcinoma or MEN2 syndrome.

Disclaimer: This product is intended for research use only. Not for human consumption, therapeutic use, or diagnostic purposes.

  • Compound Information
Detailed chemical and physical properties.
MW

4,114 Da

Amino Acids

31

Purity

≥99%

Half-Life

~7 days

Chemical Name Semaglutide
CAS Number 910463-68-2
Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight 4,113.58 g/mol
Peptide Length 31 amino acids
Mechanism GLP-1 receptor agonist (94% homology to native GLP-1)
Half-life ~7 days (enabling once-weekly dosing)
Appearance White to off-white lyophilized powder
Purity ≥99% (HPLC)
Endotoxin Level <0.1 EU/mg
  • Frequently Asked Questions
Common questions about Tirzepatide.

What is Semaglutide ?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.

Semaglutide has one of the most extensive clinical trial programs in metabolic research, including the SUSTAIN series (diabetes), STEP program (obesity), PIONEER trials (oral formulation), and SELECT trial (cardiovascular outcomes).

Semaglutide is a GLP-1-only receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. Both have shown significant efficacy, with head-to-head data (SURPASS-2) suggesting potential advantages for tirzepatide in certain endpoints.

Reconstitute with bacteriostatic water. Gently swirl—do not shake. Allow peptide to dissolve completely before use. Store reconstituted solution at 2-8°C.

Each batch is tested via HPLC for purity, mass spectrometry for molecular identity, LAL for endotoxins, and sterility testing to ensure the highest quality for research.

  • Sources & References

Peer-reviewed publications and reference materials.

Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

Wilding JPH, Batterham RL, et al.

New England Journal of Medicine (2021)

DOI: 10.1056/NEJMoa2032183

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)

Marso SP, Bain SC, et al.

New England Journal of Medicine (2016)

DOI: 10.1056/NEJMoa1607141

Semaglutide and cardiovascular outcomes in obesity (SELECT)

Lincoff AM, Brown-Frandsen K, et al.

New England Journal of Medicine (2023)

DOI: 10.1056/NEJMoa2307563

Related Products

Our products are strictly intended for laboratory research use only. Not for human or animal consumption. By purchasing, you confirm that you are a licensed researcher or purchasing for research purposes.